Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Diet, bacteria and colonic cancer (1999)
    Bingley : Emerald
    Nutrition & food science 99 (1999), S. 187-193 
    Details
    ISSN: 0034-6659
    Source: Emerald Fulltext Archive Database 1994-2005
    Topics: Agriculture, Forestry, Horticulture, Fishery, Domestic Science, Nutrition , Process Engineering, Biotechnology, Nutrition Technology
    Notes: The links between diet, bacteria and colonic cancer are examined in this article. Studies suggest that high intakes of fat and protein are associated with elevated risk of colonic cancer whereas cereals, fruits and vegetables seem to be protective. A further aspect considered in relation to this type of cancer is metabolism by gut bacteria. Probiotics, prebiotics and synbiotics are presented as ways of stimulating the activities, certain gut flora and the use of "functional foods" is also discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1108/00346659910270945
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Differential solubility of subcomponents of rat glomerular basement membrane (1984)
    Springer
    Bioscience reports 4 (1984), S. 319-326 
    Details
    ISSN: 1573-4935
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Chemistry and Pharmacology
    Notes: Abstract Marked differences were found in the electrophoretic profiles and amino-acid compositions of components prepared from rat glomerular basement membrane (GBM) by a number of different solubilization procedures. Treatment with reducing agent resulted in a simplified electrophoretic pattern which was characterized by the presence of a major collagenous component with a mol.wt, of 150 000. In contrast, detergent solubilized mainly lower-mol.-wt, material which had a more polar amino-acid composition. When both reagents were used together the majority of the basement-membrane material was soJubilized within 2 h and components with mol.wts, of 170 000 and 135 000 were predominant i n the pro-α region of the gel. Treatment for a further 16 h was required to solubilize higher-mol.-wt, material and to achieve maximum solubility of components in the pro-α region with mol.wts, of 185 000 and 150 000. These methods provide a means of separating subcomponents of rat GBM while avoiding the problems of degradation inherent in enzymatic procedures.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01140495
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies (1993)
    Springer
    Journal of neuro-oncology 15 (1993), S. 181-184 
    Details
    ISSN: 1573-7373
    Keywords: echinomycin ; central nervous system malignancies
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The objective of this trial was to determine the efficacy of echinomycin (1.2mg/m2) administered on a weekly times four schedule in the treatment of patients with recurrent or progressive central nervous malignancies despite adequate radiotherapy. Thirty-five patients were registered on study. The majority of patients (20) had glioblastoma multiforme. Ten had anaplastic astrocytoma. Eight patients had received prior nitrosoureas. SWOG performance status was 1 in 11 patients and 2 in 22. The median age was 51 years (25–75 years). One patient had a partial remission (3%:95% confidence interval: 1%–16%). Twenty two patients had progressive disease. The median survival was 5.9 months. Toxicity was primarily gastrointestinal with nausea and vomiting in 13 patients and nausea only in 11 patients. Hepatotoxicity occurred in 10 patients. Echinomycin given at this dose and schedule is not effective in treating patients with recurrent or progressive glioblastoma multiforme or anaplastic astrocytomas.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01053939
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    New agents in the treatment of primary brain tumors (1994)
    Springer
    Journal of neuro-oncology 20 (1994), S. 141-153 
    Details
    ISSN: 1573-7373
    Keywords: central nervous system tumors ; new agents
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A review of single agent trials of cytotoxic agents in adults with high grade gliomas is presented. The rationale for testing these agents in patients with brain tumors was variable and is discussed. The criteria to evaluate responses were also variable ranging from subjective evaluation of clinical improvement with a stable radiographic assessment to the same objective response criteria utilized for solid tumors. Trials of agents specifically designed for brain tumors such as AZQ and spiromustine have been disappointing. There are encouraging results being seen in early trials of newer agents which await confirmation in larger trials but which hold promise for improving the disappointing results seen so far with chemotherapy in primary brain tumors.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01052724
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group study (1985)
    Springer
    Journal of neuro-oncology 3 (1985), S. 131-135 
    Details
    ISSN: 1573-7373
    Keywords: AZQ ; carbamic acid ; central nervous system malignancies
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary AZQ, an alkylating agent with lipophilic characteristics allowing CNS penetration was studied in patients with primary CNS malignancies refractory to surgical and radiotherapeutic modalities. Responses were evaluated by three criteria: neurologic examination, performance status and CT scan of the brain. Improvement in all three parameters with stable or decreasing doses of decadron was required for a partial response. Thirty-six poor risk (prior chematherapy) patients with Grades III and IV astrocytomas were treated with 30 mg/m2. Three patients had a partial response (14, 17, 60 weeks duration). Two patients had mixed responses (worsening of one disease parameter with improvement in another), four had stable disease and one patient had improvement in neurologic parameters with a stable CT scan. Twenty-six patients had increasing disease. Fifteen good risk patients (no prior chemotherapy) with recurrent grades III and IV astrocytomas were treated at a dose of 40 mg/m2 intravenously every three weeks. There were no objective responses in this group of patients. Three patients with nonastrocytomas were treated and no responses observed. The drug was well tolerated. Myelosuppression in the form of leukopenia and thrombocytopenia was the major toxicity. Myelosuppression required dose reductions in eight patients and discontinuation of therapy due to repeated treatment delays in two patients. AZQ at doses of 30 and 40 mg/m2 given on an intermittent bolus schedule is inactive in patients with Grades III and IV recurrent astrocytoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02228889
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck (1993)
    Springer
    Investigational new drugs 11 (1993), S. 227-229 
    Details
    ISSN: 1573-0646
    Keywords: piroxantrone ; squamous cell of head and neck
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00874161
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Phase II trial of menogaril in metastatic adenocarcinoma of the prostate (1994)
    Springer
    Investigational new drugs 12 (1994), S. 67-70 
    Details
    ISSN: 1573-0646
    Keywords: prostate cancer ; menogaril ; phase II
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract Menogaril, a semisynthetic anthracycline antibiotic, was administered to patients with metastatic adenocarcinoma of the prostate. Forty-five patients with measurable disease and 45 patients with evaluable disease received 150–200 mg/m2 over 1 hour every 28 days. There were three partial responses (PR) among 87 patients evaluable for response. Myelosuppression was dose limiting. There were two deaths related to leukepenia. Other toxicities included phlebitis, alopecia, nausea and vomiting. One patient developed acute nonlymphocytic leukemia. Menogaril at these doses and schedule is toxic and has no signficant antitumor activity in metastatic adenocarcinoma of the prostate.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00873240
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study (1998)
    Springer
    Investigational new drugs 16 (1998), S. 331-332 
    Details
    ISSN: 1573-0646
    Keywords: central nervous system tumors ; Didemnin B
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006273214056
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study (1990)
    Springer
    Investigational new drugs 8 (1990), S. 77-80 
    Details
    ISSN: 1573-0646
    Keywords: mitoxantrone ; pancreatic carcinoma ; phase II trial ; DHAD ; novantrone
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin ⩽ 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00216928
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney (1992)
    Springer
    Investigational new drugs 10 (1992), S. 55-56 
    Details
    ISSN: 1573-0646
    Keywords: didemnin B ; adenocarcinoma of the kidney
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01275484
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...